Agoracom Blog Home

Archive for the ‘AGORACOM Via Satellite’ Category

The Roundup – @Novamind_Inc $NM.ca $NVMDF $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 11:04 AM on Saturday, January 8th, 2022

A weekly summary of Novamind news and media

*The above image is a rendering and may be subject to change.

Novamind Unveils New Design Concept for Clinics

We are pleased to unveil our clinic design concept to accommodate the unique requirements of psychedelic-assisted psychotherapy. The design concept will launch first in Novamind’s Park City, Utah location, and later across Novamind’s de novo clinics. Select design elements and principles will be integrated within existing clinic locations.

Inclusive and welcoming, the design concept enhances the patient experience at Novamind clinics, prioritizing patient safety and privacy, and utilizing evidence-based therapeutic elements to optimize patient care, including:

  • Biophilic designs that mimic nature and emphasize light interplay and neutral colour theory
  • Walking paths designed to minimize disruption and traffic across the clinic, creating a sense of privacy and tranquility
  • Curved treatment spaces, representing the protective space of cocoons, to facilitate the more sedentary experience of ketamine treatment
  • Larger treatment rooms to accommodate group therapy programs and support movement and more active patient behaviours associated with MDMA, psilocybin and other psychedelic medicines when approved by the FDA
  • To create the Design Concept, Novamind contracted DesignAgency, an internationally recognized interior design firm with clients that include the Four Seasons Hotels, MGM Resorts, Momofuku restaurants, Soho House and others. DesignAgency worked closely with Novamind’s clinical team to incorporate a host of therapeutic considerations into the design blueprint to achieve optimal patient experiences.

“We collaborated with Novamind’s clinical team and understood the importance of ‘set and setting’ in psychedelic medicine,” said Matt Davis, Co-Founder and Principal at DesignAgency. “The goal was to create spaces that allow patients to have a holistic experience and signal hope and healing well before they walk through the door.”

Dr. Reid Robison, Chief Medical Officer at Novamind, commented: “This new concept, combined with Novamind’s standard operating procedures, creates the most welcoming and effective healing environment possible. We wanted our clinics to be comforting, inviting and calming. With guidance from the DesignAgency team, we now have the blueprint to create spaces that elevate our patients’ healing experience.”

To see renderings of the Design Concept, click here.

January 5, 2022

View all press releases

January 4, 2022

“What is Integrative Medicine?” with Dr. Amy de la Garza

In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Steve Thayer and Dr. Reid Robison are joined by Dr. Amy de la Garza. Amy is the Substance Use Disorder Program Director at Novamind and the Medical Director of the Salt Lake City clinic. Amy is a board-certified family practice physician who for the last 10 years has been providing specialized integrative healthcare for behavioral health, substance use, and a variety of other conditions.

December 29, 2021

Essential Qualities and Skills of the Psychedelic Therapist

In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Steve Thayer and Dr. Reid Robison discuss qualities and skills they think are essential for therapists who provide psychedelic-assisted psychotherapy.

We’re celebrating 8 months of the podcast with a GIVEAWAY on Instagram! Enter to win a sweatshirt featuring the audio waves from a fan-favorite episode of Psychedelic Therapy Frontiers.

Learn more, subscribe and catch up on previous episodes you may have missed at psychedelictherapyfrontiers.com

Email us questions and feedback at [email protected].

December 23, 2021

Novamind Expands To Arizona

Benzinga covers our expansion into Arizona highlighting the signed definitive agreement to acquire the Foundations for Change clinics. 

View all media

Health Canada’s Special Access Program Will Now Allow Doctors To Request Patient Access To Psychedelics

This is big news for Canada overall. “Long-awaited amendments to Health Canada’s Special Access Program have finally been made, potentially opening the door to less onerous access to the medical access of psychedelics like psilocybin and MDMA for patients in need.” Our mission has always been to increase access to these life-changing therapies and drugs in safe and regulated settings. We celebrate this news and will continue to do our part to bring psychedelic medicine to as many people in need as possible.   

Psychedelic Healthcare in 2021

PSYCH covers the year in psychedelic healthcare. “2021 was a seminal year for psychedelic medicine, with data released from groundbreaking clinical trials harnessing MDMA and psilocybin.” 2021 was special, but we can’t wait to work on making 2022 even more impactful for people around the world. For more great psychedelic content from PSYCH, download the third edition of the Psychedelics as Medicine Report here.

Ketamine Therapy Swiftly Reduces Depression and Suicidal Thoughts

Dr. Reid Robison and the team at Novamind have spent years providing ketamine-assisted psychotherapy and seeing the positive benefits firsthand. It’s changed the lives of thousands of our patients. We recently published a story about how ketamine helped a mother struggling with severe depression and a struggling marriage. You can read it here. Seeing the results of this systematic review by the University of Exeter is both exciting and validating. “Ketamine therapy has a swift short-term effect on reducing symptoms of depression and suicidal thoughts, according to a review of all the available evidence.”

For further information, email us: 
[email protected]

We’re hiring!
Check out current opportunities to join our growing team.

Was this email forwarded to you?
Subscribe to our weekly newsletter

VIDEO – Logiq Hits Record Quarter At $12.3M Preliminary Revenues. Expects $48M Before M&A And Spinout Of South East Asia Tech In 2022

Posted by AGORACOM-JC at 5:25 PM on Thursday, January 6th, 2022
Logic logo 300x100

The global e-commerce market surpassed $9 TRILLION in 2019 … and is scheduled to grow by a CAGR of 14% into 2027 … But mega brands control almost 70% of the US market alone and are using their strength to win even more market … making it harder for SMBs to compete in this massive market.    

Logiq …. a public company for just 4 months…. is an award-winning e-commerce and fintech solutions company that is addressing that problem by helping drive e-commerce for SMBs around the world … with revenues of $37.9M in 2020 …. from 2 divisions:    

AppLogiq (Agreement finalized to Transfer AppLogiq Assets into Publicly Traded Subsidiary) – In Southeast Asia AL offers a mobile application development platform as-a-service which enables hundreds of thousands of SMBs to create mobile apps with little technical expertise or know-how …  Offered across Southeast Asia, Europe and U.S. in 14 languages .. …. also offers a mobile fintech payment platform (PayLogiQ) and a hyper-local food delivery service (GoLogiq)    

DataLogiq – provides a data-driven, end-to-end e-commerce marketing solution that integrates AI to help SMBs in need of online marketing solutions.    

Financial Highlights: 

  • 2020 revenue of $37.9 million … 31% CAGR since 2016
  • Revenue H1-21 $16.4 million
  • Revenue Q2-21 $8.3 million …
    • margin of 29.5%
    • up 16.4 percentage points from the year-ago quarter.
  • Revenue Q3-21 $7.8 million
    • margin for DataLogiq: improved from 18.9% to 28.2%.
    • margin for AppLogiq: improved from 12.1% to 31.7%.
  • Q4-21 Revenue Estimate: $12.3 million, up 87% vs Q4-20
    • Gross margin expected to 34.0% vs 29.5% in the previous Q / 21.1% in Q4-20

Brent Suen, president of Logiq commented,

“Our improving revenue performance throughout 2021 demonstrates our team’s commitment to driving a transformation of our business overall and providing visibility on future profitability. As we refocused our efforts on higher quality, more profitable revenue streams and adjusted to the changing market dynamics, we also drove strong gross margin improvement every quarter of 2021. In fact, our gross margin more than doubled in Q4 2021 compared to the full year of 2020.”

Suen continued,

“We believe this strong progress across the board is keeping us on the path to profitability for both of our business segments,” continued Suen. “It also advances our plans to separate our DataLogiq and AppLogiq businesses into two independent publicly traded companies as another way to further unlock shareholder value.”

Now sit back, relax and watch this powerful interview.

VIDEO – Valeo Pharma Immune Booster Now Available In ~300 Stores Under Loblaws Banner, Another Step Closer to 2025 Revenue Target of $160M

Posted by AGORACOM-JC at 1:40 PM on Thursday, January 6th, 2022
Valeo pharma 300x300

Valeo Pharma is already a successful, revenue-generating, small-cap Canadian pharmaceutical company that acquires the Canadian rights to commercialized drugs in other parts of the world that don’t have Canada on their radar as a target market.    

This “in-license” business model is ingenious because it means ZERO developmental or clinical risk, which is the downfall of most small-cap pharma companies.     

The company released stellar a Q3 with the following highlights:    

  • Record revenues of $5.7 million for Q3 2021, up 280% over Q3 2020 and 114% over prior quarter.
  • Record gross margin of $2.2 million , up 1602% over Q3 2020 and 204% over prior quarter.
  • Record 9 months revenues at $10.2 million , up 94%

But wait, there’s more…

The company announced that Hesperco™ Is Now Available At Loblaws, Hesperidin Covid-19 Clinical Trial Results Submitted For Publication.

  • Approved by Health Canada for immune support, is now available for sale in approximately 300 stores under the Loblaw’s banners including:
    • Loblaws
    • Dominion,
    • Zehrs,
    • Fortinio’s,
    • Your Independent Grocer and Superstore

Steve Saviuk , CEO commented,

We are very pleased to announce that Hesperco is now available in over 300 Loblaw banner stores. The immune support properties of hesperidin, the sole medicinal ingredient contained in Hesperco capsules, has been well documented in numerous scientific publications. We are also encouraged by the results of the Hesperidin Covid-19 clinical trial which has recently been submitted for publication. The study concluded that hesperidin could have beneficial effects and may help reduce certain Covid-19 symptoms. The publication further suggested that earlier treatment of longer duration and/or higher dosage should be studied.”

But wait, there’s more…

The company Closed Previously Announced Upsized $15 Million Bought Deal Private Placement And Concurrent $10 Million Private Placement with Investissement Québec.

Now sit back, relax and watch this powerful interview with Valeo Pharma.

VIDEO – Liquid Avatar Metaverse Sales Hit $1,000,000 In Preliminary Gross Revenue – Setting Up Big 2022 and Potential Token Offering

Posted by AGORACOM-JC at 6:11 PM on Wednesday, January 5th, 2022
Liquid avatar logo v1 nk

The genesis of Liquid Avatar Technologies is a global blockchain & personal identity solutions company specializing in empowering individuals to manage, control and generate value from their biometrically-verified digital Identity, which also provides businesses and governments the ability to easily integrate digital wallets and digital identity solutions through its Liquid Avatar platform (www.liquidavatar.com

And if the story ended there, that would be more than enough to build a company on.

However, as the digital universe has continued to expand, there is an ever-increasing need to verify online identity as governments and enterprises around the world prepare for the shift.  For example:

  • In early 2021 Google announced a major shift away from precision-targeting of ads based on everything you do on the internet
  • The Ontario Government released its Digital Strategy, with key themes including the launch of Digital ID credentials. 

“Ontario is one of the first jurisdictions in North America to announce that it will issue and enable digital credentials – and it has been a great experience working with the government on this both directly and through our role in membership organizations like the Trust Over IP Foundation,

As a result, the Liquid Avatar Verifiable Credentials Ecosystem (LAVCE) is being built to support all participants in a digital credential ecosystem.  Almost immediately, Liquid Avatar announced a big win here by partnering with the Ontario Convenience Stores Association (OCSA) To Provide Digital Age-Verification Solutions To Over 8,000 Stores.

Again, if the story ended there, Liquid Avatar would have the makings of a potentially massive tech company.

But with the rise of NFTs and the Metaverse, both of which strongly rely on digital identity, the Company continued to expand its core digital identity technology into these areas and registered major successes, including $1,000,000 in Preliminary Gross Revenues for its Aftermath Islands Metaverse.

In the Company’s Q4 Recap and Business Update CEO David Lucatch stated: 

“Our in-market businesses continued to perform above expectations for Q4, and we remain optimistic, while cautious, as these are still early days in the Company’s transformation to an active revenue organization. We have started to witness online acceptance of digital identity programs, which are at the core of all our solutions, and both avatar and metaverse activities are gaining traction, creating opportunities for early revenue there, as the industry embraces the future of Web 3.0. Our goal is to continue to create value for all our stakeholders.”

If you believe in the future of Web3 (blockchain, crypto, tokens, NFTs and the Metaverse) and looking for a small cap company to help you participation in it, then look no further than Liquid Avatar.  

Watch this powerful interview with CEO David Lucatch.

VIDEO – Fobi AI Year In Review – A Must See 1-Hour Jam Session

Posted by AGORACOM-JC at 4:24 PM on Thursday, December 30th, 2021
Fobi AI Inc.

FOBI AI is a global leader in digital wallet pass technology that delivers real-time data analytics and engagement through artificial intelligence to drive customer activation and engagement in stores, stadiums, arenas, hotels and other large venues around the world.  

More than just lip service, FOBI AI is firing on all cylinders. Here are just some of the highlights from December:

Some excerpts from CEO Rob Anson:

  • “Big names out of the gate in Q1”
  • “Plenty Wow I didn’t see that coming moments”

Sit back, relax and watch this power Fobi AI Year In Review.

The Roundup – @Novamind_Inc $NM.ca $NVMDF $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 10:18 AM on Saturday, December 25th, 2021

The Roundup

A weekly summary of Novamind news and media

Dr. Steve Thayer with an important reminder that, for some, the holidays can be a difficult time of year for many reasons. He shares tips to care for our mental health and wellbeing over the holidays.

Watch on Instagram.

Novamind Signs Definitive Agreement to Acquire Arizona-based Clinics

We are pleased to announce the signing of a definitive agreement to acquire Arizona-based Foundations for Change, a mental health practice specialized in ketamine-assisted psychotherapy, from its sole stockholder, Jeff Edelman. The transaction is subject to regulatory approvals and is expected to close in January 2022.

Opened in 2017 by Jeff Edelman, Foundations currently operates one outpatient mental health clinic in Peoria, Arizona with an annual revenue run rate in excess of US$800,000 and owns a second, larger location in Phoenix that is scheduled to open in early 2022. Foundations will temporarily operate as “Foundations for Change by Novamind” until the Company completes its recently announced rebrand. Mr. Edelman will continue in a leadership capacity as Medical Director for both clinics. Mr. Edelman is double board-certified Family Psychiatric-Mental Health Nurse Practitioner and a Child and Adolescent Psychiatric-Mental Health Clinical Nurse Specialist. As a former military combat veteran, who served in the US Army 55th Medical Co. Combat Stress Control unit, Mr. Edelman has special expertise in treating military veterans and first responders who struggle with stress and trauma.

Read the full release here.

December 23, 2021

View all press releases

December 21, 2021

Horizons: Perspectives on Psychedelics Conference Recap

In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Steve Thayer and Dr. Reid Robison catch up after their recent trip to the “Horizons: Perspectives on Psychedelics” conference in New York. Stay tuned next week for our last episode of 2021 and a special PTF podcast contest and giveaway.

Learn more, subscribe and catch up on previous episodes you may have missed at psychedelictherapyfrontiers.com

Email us questions and feedback at [email protected].

With Health Care Workers Hurting, a Doctor Wants to See if a Psychedelic Can Help

NBC News reports on a first-of-its kind clinical trial at the University of Washington School of Medicine to treat 30 medical professionals experiencing depression with a dose of synthetic psilocybin combined with psychotherapy. Some say that even five years ago, this would have been considered taboo. “That medical researchers are turning toward psilocybin to treat colleagues is representative of a growing curiosity and acceptance of the drug among those in the medical establishment.” We’re seeing that openness, too, through our Frontline KAP clinical pilot to help healthcare workers heal.

Psychedelic-Assisted Therapy on the Rise in VA Hospitals

Lucid News covers how research partnerships exploring psychedelic-assisted psychotherapy as treatment option for veterans are gaining traction.

For further information, email us: 
[email protected]

We’re hiring!
Check out current opportunities to join our growing team.

Was this email forwarded to you?
Subscribe to our weekly newsletter

BEYOND THE DECK – Blockchain Foundry SYSCOIN Market Cap Is $455 MILLION. 24 Hour Trading Volume $13M + … What Does Web 3 Know?

Posted by AGORACOM-JC at 5:20 PM on Tuesday, December 21st, 2021
Logo

We all remember the crash of “blockchain” stocks a couple of years back, which was actually a crash of blockchain pretenders who used the term to build stock promotions, as opposed to building actual blockchains.  

Like the dot-com crash of 2000, which bankrupted “dot-com” companies but gave birth to the likes of Google, Amazon, Linkedin because they built actual utility and value, the same could be expected of the blockchain crash and its’ resurgence.  

Blockchain Foundry Is A Smallcap Blockchain 2.0 Company with Real Customers, Products, Revenues and A Web3 Market Cap Of $455,000,000 For It’s Syscoin

But Blockchain Foundry is only just getting started.  The Company is building a WEB3 ecosystem on top of its powerful Sycoin blockchain which is the 2nd most secure blockchain in the world next to Bitcoin.  That isn’t a typo and Web3 coin investors believe it given the fact it has traded over $13,000,000 in volume over the last 24 hours … and close to $25,000,000 in the 24 hours before that!

What do they know that small cap investors don’t know?  What to Web3 investors know that isn’t being reflected in the $BCFN stock price? The short answer is .. A Lot … but luckily we were able to tear away CEO Dan Wasyluk from his coding marathons to explain exactly what we are missing by going through the Company’s power point presentation.

If you’re a small cap investor looking for exposure to the Web3 world of blockchain, coins, tokens, NFTs and more then this $BCFN presentation is a must-watch.

Buckle Up for one hell of a great presentation!

VIDEO – Valeo Pharma Obtains Public Reimbursement For Asthma Drugs In Quebec and Nova Scotia, Another Step Closer to 2025 Revenue Target of $160M

Posted by AGORACOM-JC at 4:38 PM on Friday, December 17th, 2021
Valeo pharma 300x300

Valeo Pharma is already a successful, revenue-generating, small cap Canadian pharmaceutical company that acquires the Canadian rights to commercialized drugs in other parts of the world that don’t have Canada on their radar as a target market.   

This “in-license” business model is ingenious because it means ZERO developmental or clinical risk, which is the downfall of most small cap pharma companies.    

Q3 Highlights:   

  • Record revenues of $5.7 million for Q3 2021, up 280% over Q3 2020 and 114% over prior quarter.
  • Record gross margin of $2.2 million , up 1602% over Q3 2020 and 204% over prior quarter.
  • Record 9 months revenues at $10.2 million , up 94%

Clearly, Valeo Pharma is firing on all cylinders. This is evident by the company’s recent announcement that they Obtained Public Reimbursement For Enerzair® Breezhaler® And Atectura® Breezhaler® In Quebec And Nova Scotia.

  • Public reimbursement now includes Alberta , Quebec and Nova Scotia , representing approximately 37% of the Canadian population.
  • More than 90% private insurance coverage across Canada

Frederic Fasano, Valeo’s President and Chief Operating Officer commented,

“We are pleased to be reporting today the addition of Quebec and Nova Scotia to join Alberta on the list of provincial public coverage secured for both asthma medications. Public Reimbursement access makes a meaningful impact for asthma patients left with no coverage so far, and also simplify health care providers procedures to provide access of both medications to their patients. Enerzair and Atectura are innovative asthma therapies that are helping make asthma control a more attainable goal for Canadians asthma patients”.

But wait, there’s more…

The company just Closed Previously Announced Upsized $15 Million Bought Deal Private Placement And Concurrent $10 Million Private Placement with Investissement Québec.

Now sit back, relax and watch this powerful interview with Valeo Pharma.

VIDEO – Intema Discusses Isle of Man license, LOI to Enter US Market, Loop.Bet Acquisition “97% Done” + More

Posted by AGORACOM-JC at 9:09 AM on Thursday, December 16th, 2021
Screen shot 2021 04 12 at 5.55.14 pm

An emerging esports and iGaming company  that is creating an Esports adventure like no other ….  Create the world’s foremost esports and iGaming ecosystem. 

The global online gambling market could potentially hit $1 TRILLION by the end of this decade.  The  obvious reasons include the following: 

  • Exponential growth in the number of people online.  Yet only 59% of the world means more to come.
  • Fast growth in the number of countries and jurisdictions legalizing gambling to collect tax revenue. 

Esports was already the fastest growing sub-sector of digital entertainment, and Covid 19 has only accelerated this trend. 

  • Biggest brands/tournament prizes / online audiences in the world … 500M + 
  • The International Olympic Committee has recognized esports as a sport, and it will be a medal event at the 2022 Asian Games

Despite the vast amount of viewers, esports is still dramatically under-monetized relative to traditional sports. ITM believes wagering will play a major role in helping monetize this ever-evolving platform.

Intema has had an active first half of December evident by the following:

The company’s U.S subsidiary Generationz Gaming Entertainment signs letter of intent with Wild Rose Entertainment.

Why is this important?

  • Goal of expanding Intema’s esports and iGaming operations in the U.S.
  • letter of intent with Wild Rose Entertainment to operate a LOOT.BET sports wagering skin in the state of Iowa
  • Betting handle in Iowa estimated at more than US$1 billion in 2021, having reached $287 million in November 2021 (Source: gambling.com, December 10, 2021)

Laurent Benezra, President and CEO of Intema,

“We are thrilled to welcome Bill to the Intema team and are impressed with what he has managed to accomplish in a very short period of time. The LOI with Wild Rose is just the beginning of what the LOOT.BET platform could bring to Intema once its acquisition is finalized.” 

But wait, there’s more…

The company announced granting of Isle of Man online gambling license

Benezra commented further,

“The grant of the Isle of Man gambling license is major news for Intema and will have a significant positive impact on our future activities. In particular, it allows us to comply with one of the TSX Venture Exchange’s main conditions for closing the acquisition of Livestream Gaming Inc. (“ Livestream ”), with its LOOT.BET online gaming platform. It will also enable us to conduct our iGaming activities through one of the world’s most prestigious gaming jurisdictions and, once we acquire our LOOT.BET platform, to white-label it to regulated gaming markets on a global scale. Finally, it gives LOOT.BET the same level of credibility as other online gambling platforms, throughout the gaming community and among our peers.”

Sit back, relax and watch this powerful interview.

The Roundup – @Novamind_Inc $NM.ca $NVMDF $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 9:08 AM on Saturday, December 11th, 2021

The Roundup

A weekly summary of Novamind news and media

Novamind Opens New Clinic with Specialized Focus on Substance Use Disorders

Salt Lake City Clinic welcomes incoming addictions specialist, Dr. Amy de la Garza

We are pleased to announce the opening of a new clinic located in downtown Salt Lake City (SLC). In addition to Novamind’s suite of mental health treatments, the SLC Clinic specializes in integrative behavioural health and services for adults with substance use disorders (SUD) led by incoming Medical Director, Dr. Amy de la Garza.

The SLC Clinic’s outpatient SUD services provide an alternative to residential treatment programs and work to address the highly complex public health crisis that is worsening alongside challenges related to access. In 2020 alone, 93,000 Americans died of a drug overdose-an increase of 30 per cent from the previous year, according to the Centers for Disease Control and Prevention.

Dr. Reid Robison, Novamind’s Chief Medical Officer, commented: “Social isolation and despair related to the COVID-19 pandemic have further fueled a significant increase in substance use disorders and related deaths. Dr. de la Garza’s expertise in addiction medicine and behavioural health is a vital addition to our team as we continue to expand Novamind’s clinic footprint to address unmet need and broaden our innovative, evidence-based treatments.”

Dr. de la Garza is a board-certified family practice physician with 10 years of experience providing specialized care for patients with behavioral health and SUD diagnoses. She earned her Doctorate in Medicine from the University of Colorado before completing a Family Medicine Residency at the Utah Healthcare Institute. She also completed an Addiction Medicine Fellowship at the University of Utah and is an Institute for Functional Medicine Certified Practitioner. In 2017, Dr. de la Garza opened the first community-based, co-located primary care and behavioral health practice in Salt Lake City, Utah.

“I am thrilled to join Novamind and look forward to establishing an innovative outpatient substance use disorder program that brings together addiction and integrative medicine and treats the whole person,” said Dr. de la Garza, who is also trained in integrative modalities and lifestyle medicine, including nutrition, movement, sleep, stress management and social connection.

Novamind will collect clinical data on the efficacy of the integrative treatment approach for SUD and host upcoming studies for conditions like opioid use disorder. Additionally, the SLC Clinic will pilot an innovative and cost-effective group medical visit model that has been shown to reduce anxiety and depression, as well as improve outcomes in chronic conditions like cardiovascular disease and diabetes.

The SLC Clinic is located at 807 E South Temple, Suite 101, Salt Lake City, Utah.

December 6, 2021

View all press releases

December 7, 2021

Anxiety: Why We Worry and What to Do About It

In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Steve Thayer and Dr. Reid Robison explore anxiety. They discuss the following topics and much more:
• What is an anxiety disorder?
• Anxiety management skills
• The role of medicines in treating anxiety

Learn more, subscribe and catch up on previous episodes you may have missed at psychedelictherapyfrontiers.com

Email us questions and feedback at [email protected].

December 10, 2021

Ketamine-Assisted Therapy Is Having a Moment in Utah

Utah Business covers Dr. Reid Robison and the success of ketamine-assisted psychotherapy in our clinics. “While it’s still early and much more testing is to be done, Robison describes what’s happening in mental health care as a ‘psychedelic renaissance’.”

December 9, 2021

Doors Open in SLC

Benzinga covers the opening of our Salt Lake City clinic and future substance use disorder program led by Dr. Amy de la Garza.

December 9, 2021

Panel: International Summit on Psychedelic Therapies

Dr. Reid Robison, Matt Johnson and Robin Carhart-Harris discuss The Science of Psychedelics: Therapeutic mechanisms and clinical outcomes for a range of mental illnesses and other conditions.

December 8, 2021

Psychedelics & Eating Disorders

Chief Medical Officer Dr. Reid Robison’s keynote presentation at the Mind Medicine Australia International Summit on Psychedelic Therapies for Mental Illness.

View all media

Opioid Overdoses Are A Raging Public Health Crisis, Driven Mostly By Illicit Fentanyl And Heroin

“While the U.S. has been battling Covid-19 it’s gotten lost in the shuffle that the nation had record numbers of drug overdose-related deaths in 2020; approximately 93,000. In addition, from May 2020 through April 2021, the figure rises to 100,000.” We need better treatment options for people with substance use disorders (SUD). It’s the driving force behind why incoming Novamind Medical Director Dr. Amy de la Garza will lead SUD programming at our new Salt Lake City clinic.  

Psychedelics are Poised to Change the Course of Mental Health Treatment

We are currently in a mental health crisis. Depression, anxiety and symptoms of PTSD have run rampant over the last two years, accelerated by the COVID-19 pandemic and its far-reaching effects. The need for new and effective mental health treatments has never been clearer. We have seen the efficacy of ketamine-assisted psychotherapy firsthand. And we are eager to continue psychedelic research. If you’d like to stay up to date on upcoming studies hosted by Novamind, visit us here and get in touch. “So what else does the future hold for psychedelics? For one thing, taking psychedelics could one day be the same as taking an everyday pill prescribed by your doctor.”

For further information, email us: 
[email protected]

We’re hiring!
Check out current opportunities to join our growing team.

Was this email forwarded to you?
Subscribe to our weekly newsletter